Evidence map›Paper›PMID 41353530›Full record

ArticleBMC infectious diseases2025

Severe Rhodococcus equi pneumonia following hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib in hepatocellular carcinoma: a case report.

Fang Luo, Ping Yao, Qingxian Cai, Minke He, Li Xu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fang Luo *Department of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518112, P.R. China.
Ping Yao *Department of Liver Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat- sen University Cancer Center, Guangzhou, 510060, P. R. China.
Qingxian CaiDepartment of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518112, P.R. China.
Minke HeDepartment of Liver Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat- sen University Cancer Center, Guangzhou, 510060, P. R. China.
Li XuDepartment of Liver Surgery, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat- sen University Cancer Center, Guangzhou, 510060, P. R. China. xuli@sysucc.org.cn.

Funding

This work was supported by Shenzhen High-level Hospital Construction Fund NA
6 · The paper itself

Abstract

Rhodococcus equi is a Gram-positive aerobic bacterium primarily associated with pulmonary infections in animals. Although rare in humans, such infections typically affect immunocompromised individuals, often presenting with severe pulmonary manifestations such as lung abscesses or cavitary pneumonia. This report describes a patient with advanced hepatocellular carcinoma (HCC) who developed cavitary pneumonia after receiving hepatic arterial infusion chemotherapy combined with sintilimab and lenvatinib. Diagnosis of Rhodococcus equi infection was confirmed via bronchoalveolar lavage fluid (BALF) analysis. The infection was successfully managed with an adjusted antibiotic regimen of imipenem/cilastatin, levofloxacin, and amikacin.

Indexed as

Actinomycetales InfectionsAntibodies, Monoclonal, HumanizedCarcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsPneumonia, BacterialQuinolinesRhodococcus equiAmikacinAnti-Bacterial AgentsAntineoplastic AgentsBronchoalveolar Lavage FluidCilastatinHumansLevofloxacinMaleAmikacinAnti-Bacterial AgentsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCilastatinlenvatinibLevofloxacinPhenylurea CompoundsQuinolinessintilimabCavitary pneumoniaHepatocellular carcinomaLenvatinibRhodococcus equiSintilimab

Identifiers

PMID41353530
PMCPMC12817617

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.